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GOLDproposedaCOPDassessment framework focussedonsymptomsmeasuredbytheCOPDAssess-
ment Test (CAT) or themMRCand onexacerbation risk basedonpoor lung function (FEV1<50%) or
a history of 2 exacerbations in the previous year. This analysis examined the characteristics of
COPD patients recruited from routine clinical settings and classified using the GOLD framework.
1041 European COPD patients (38.5% from primary care) from the Adelphi Respiratory Disease
Specific Programme with information on CAT, mMRC, spirometry and exacerbation history in the
previous year were analysed. Their mean age was 64.9  9.9 years and mean FEV1 was
62.5 17.8% predicted; 80% were in GOLD 2 spirometric grade or milder.
CATandmMRC cut points identifieddifferent groups of patients; using CAT, the compositionwas:
GroupA9.3%,GroupB 48.5%,GroupC 0.7% andGroupD41.5%. 80%wereclassified as high riskbased
onexacerbationhistory and25%ofpatients in a lowrisk category (GOLDAandB)had1exacerbation
in the previous year. The incidence of diabetes, hypertension and hyperlipidaemia rose with wors-
ening GOLD group (all p < 0.0001); diabetes GOLD A 4%, GOLD B 16%, GOLD D 29%; hypertension
GOLD A 38%, GOLD B 55%, GOLD D 65%; hyperlipidaemia GOLD A 13%, GOLD B 30%, GOLD D 37%.
In patients seen in routine clinical settings, 25% of GOLD low risk patients had one exacerbation
per year and the incidence of cardio-vascular and metabolic diseases increases with worsening
GOLD group.
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performed in France, Germany, Italy, Spain and the UKTable 1 Patient disease characteristics.
Parameter n %
FEV1 50% predicted 828 79.5
FEV1 <50% predicted 213 20.5
0 Exacerbations in past 12 months 506 48.6
1 Exacerbations in past 12 months 193 18.5
2 Exacerbations in past 12 months 342 32.9
CAT score 0e9 104 10.0
CAT score 10e19 319 30.6
CAT score 20e29 449 43.1
CAT score >30 169 16.2
mMRC score 0 221 21.2
mMRC score 1 311 29.9
mMRC score 2 238 22.9
mMRC score 3 190 18.3
mMRC score 4 81 7.8It is now well recognised that chronic obstructive pulmo-
nary disease (COPD) is a complex disease [1]. Until recently,
spirometry remained the standard method for confirming a
clinical diagnosis of COPD and for grading COPD severity [2].
It is now accepted that forced expiratory volume in one
second (FEV1) is an insufficient marker of the severity of the
disease. The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2011 strategic document has proposed a
new, multidimensional approach to assess patients with
COPD [3]. It recommends that COPD management and
treatment should consider both disease impact, deter-
mined by assessment of symptoms and activity limitation,
and the future risk of exacerbations, determined from
airflow limitation or exacerbation history [4]. This com-
bined assessment of COPD results in the classification of
patients into one of four groups: A: low risk, less symptoms;
B: low risk, more symptoms; C: high risk, less symptoms; D:
high risk, more symptoms. GOLD also recommends looking
for, and treating if present, those co-morbidities that often
co-exist with COPD [3].
GOLD advocates either the COPD Assessment Test (CAT)
or the modified Medical Research Council (mMRC) dyspnoea
scale for assessing symptoms [3]. The CAT is a short, 8-item,
health status questionnaire developed to provide a simple
tool for quantifying the overall symptomatic impact of
COPD [5]. It has been shown to distinguish between
different severities of COPD and is highly correlated with
the St George’s Respiratory Questionnaire (SGRQ) [6]. The
modified MRC dyspnoea scale (mMRC) was developed to
help physicians establish clinical grades of breathlessness
for their patients with emphysema, based on their ability to
perform physical activities [7]. It is significantly associated
with shuttle distance, SGRQ scores and Chronic Respiratory
Questionnaire scores [8]. GOLD suggests either a CAT score
of 10 or mMRC 2 as equivalent cut-points for symptoms
to categorise patients into the high symptom group. Three
recent publications have reported patient characteristics
using the GOLD 2011 system in research cohorts [9e11].
One of those is a population survey [9], the second is a
cohort study that included people with COPD identified
through screening [10] and the third reported data from
Spanish COPD research cohorts studied in secondary and
tertiary care centres [11]. None of these studies fully re-
flected the type of patients seen in routine clinical
practice.
The primary aim of this analysis was to examine the
distribution and clinical characteristics of COPD patients
categorised according to the 2011 GOLD assessment
framework using data from a combined European primary
and secondary care routine clinical practice patient
population.
Methods
The data for this analysis originated from the Adelphi Res-
piratory Disease Specific Programme (DSP), an interna-
tional, cross-sectional survey, conducted under market
research guidelines. The survey was conducted through
physicians (Primary Care and Pulmonologists or equivalent)actively involved in managing patients with COPD. It was
between June and September 2011. The full methodology
has been published previously [12].
Participating physicians completed a patient record
form for six consecutive consulting COPD patients from
their clinic, and invited the same patients to voluntarily fill
out a self-completion form. Although not a random sample,
the physicians providing the information had no control
over which of the eligible patients in their care presented in
their clinic during the data collection period, so the sample
should be representative of the consulting population. All
diagnostic, treatment procedures and choices were left at
the discretion of the treating physician. No tests or in-
vestigations were performed as part of this research. Co-
morbidities were recorded by physicians.
The survey was performed according to the European
Pharmaceutical Market Research Association guidelines
[13]. Each patient provided consent for de-identified and
aggregated reporting of research findings as required by the
guidelines. All data were de-identified prior to receipt by
Adelphi.
Physicians were asked for information regarding the
most recent FEV1 measurement and exacerbation history in
the previous 12 months. Patients were asked to complete
the CAT [5] and the mMRC [7]. An exacerbation was defined
as an increase in symptoms not brought under control by
rescue medication. Only patients with a spirometric
assessment, and completed exacerbation history, CAT and
mMRC in the last year were included in this analysis.
A recent report suggests that CAT 10 and mMRC 2
identify different groups of patients [14] and that a mMRC
cutpoint of 1 is more comparable to CAT 10, so this
analysis will focus on a comparison of the GOLD groups
categorised using the CAT health status measure since it is
more comprehensive than the mMRC. Comparisons were
made across GOLD groups using standard univariate tests,
the type of test used depended on the type of variable
being compared. Numeric variables were compared using
ANOVA, whereas categorical variables were compared
using chi-squared tests. Significance was accepted at
p < 0.05.
Table 2 Patient allocation to GOLD groups using CAT and
mMRC cut-points.
GOLD
group
Symptoms Risk Symptoms
categorised
using CAT
n (%)
Symptoms
categorised
using mMRC
n (%)
A Low Low 97 (9.3) 393 (37.8)
B High Low 505 (48.5) 209 (20.1)
C Low High 7 (0.7) 139 (13.4)
D High High 432 (41.5) 300 (28.8)
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Study population
A total of 488 physicians completed patient record forms on
2894 patients. Out of these, 1041 patients met the inclusion
criteria for this analysis of which 393 (38.5%) were from
primary care physicians and 648 (61.5%) from specialists.
The two main reasons for exclusion from the analysis were
that not all patients agreed to complete a questionnaire
and FEV1 tests were not performed or results were un-
available. Germany provided a larger contribution of pa-
tients (34.7%) than other countries (Spain 18.5%; France
18.4%; UK 14.4%; Italy 13.9%). This largely reflects the dif-
ferences in the proportion of patients who agreed to fill in a
self-completion form across the countries. The majority of
patients had an FEV1 50% predicted (79.5%) (Table 1).
When split by GOLD categories, the number of patients in
each group was: 16.4% (FEV1 >79% GOLD 1), 63.1% (FEV1
50e79% GOLD 2), 15.9% (FEV1 30e49% GOLD) and 4.5% (FEV1
<30% GOLD 4). Half (48.6%) had no exacerbations reported
in the previous year; good health status (CAT <10) was
reported by 104 subjects (10%) and 15.1% used some form of
oxygen. The patients managed in primary care were slightly
milder than those in secondary care, as evidenced by more
patients in GOLD Stage 2 (87% vs 75%) and more MRC <2
(59% vs 46%), CAT scores and exacerbations rates were very
similar.
Use of CAT or mMRC score to categorise patients
There was a significant positive correlation between the
mMRC and CAT (F Z 115.47, p < 0.0001, adjustedTable 3 Demographic characteristics by GOLD group based on
Group A Group B
CAT mMRC CAT mM
No. of patients (%) 97 (9.3%) 393 (37.8%) 505 (48.5%) 20
Age, mean (years) 61.9 62.6 63.6 64
Male, % 72% 73% 72% 72
Current smoker, % 29% 32% 32% 29
Mean time diagnosed
(years)
4.0 4.1 4.5 5.2
White/caucasian (%) 97% 97% 95% 92R2 Z 0.31). The distribution of patients into the GOLD
groups, as categorised by CAT or mMRC are shown in Table
2. Nearly half (51.2%) were placed in the low symptom
groups (GOLD groups A and C) by the mMRC, compared to
10% so categorised by the CAT. Less than 1% of patients
were included in group C using the CAT compared to 13.4%
with the mMRC. The differences in demographic charac-
teristics of patients categorised into the four GOLD groups
using the CAT were small (Table 3). The differences in in-
dividual symptoms categorised into the four GOLD groups
using the CAT or mMRC is shown in the online supplement,
Table 1.
Exacerbations
In the previous 12 months, 48.6% of patients had no exac-
erbations but 32.9% had two or more, 151 (25%) of patients
in groups A and B had one exacerbation. The frequency of
reported exacerbations in each GOLD group classified using
CAT and mMRC is shown in Table 4. Whilst GOLD provides
two criteria for inclusion in the high-risk group, nearly 80%
of patients in Group D had 2 exacerbations in the pre-
ceding year (Figs. 1 and 2). When classifying patients in
groups A and B by GOLD 2013 which recommends using
hospitalisation for COPD exacerbation as the highest risk,
the distribution of patients is shown in Table 5.
Comorbidity rates categorised by GOLD group
The percentage of patients with metabolic and cardiovas-
cular co-morbidities was high (Table 6). There was a clear
trend for higher co-morbidity in patients with more symp-
toms irrespective of whether assessed by CAT or mMRC and
more exacerbations (except for group C which had too few
patients to yield meaningful conclusions). Other comor-
bidities experienced by 5% of the total patients, split by
GOLD group are shown in the online supplement, Table 2.
Discussion
This analysis of data, obtained in COPD patients being
reviewed in routine primary and secondary care settings
shows that only a small proportion have a low level of
symptoms as assessed by the CAT. A higher proportion was
judged asymptomatic using the narrower dyspnoea focus of
the mMRC. The more symptomatic patients were splitCAT score 10 and mMRC 2.
Group C Group D
RC CAT mMRC CAT mMRC
9 (20.1%) 7 (0.7%) 139 (13.4%) 432 (41.5%) 300 (28.8%)
.5 59.1 65.6 67.3 67.9
% 71% 65% 69% 71%
% 35% 47% 33% 30%
6.3 6.1 7.6 8.3
% 57% 91% 95% 96%
Table 4 Distribution of patients based on exacerbation history (symptoms assessed using CAT and mMRC score).
Exacerbation frequency in the last 12 months
GOLD group 0 1 2
CAT mMRC CAT mMRC CAT mMRC
A 83 (85.5%) 311 (79.1%) 14 (14.4%) 82 (20.9%) 0 (0%) 0 (0%)
B 368 (72.9%) 140 (67.0%) 137 (27.1%) 69 (33.0%) 0 (0%) 0 (0%)
C 3 (42.9%) 25 (18.0%) 1 (14.3%) 12 (8.6%) 3 (42.9%) 102 (73.4%)
D 52 (12.0%) 30 (10.0%) 41 (9.5%) 30 (10.0%) 339 (78.5%) 239 (79.9%)
Data are number of patients in each exacerbation category and the percentages apply to the number of patients in each exacerbation
category by GOLD group.
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exacerbations and those at higher risk.
The GOLD selection of CAT 10 as the boundary be-
tween less and more severe symptoms was based on a
recent analysis of CAT scores [15], but at that time the
relationship between CAT and mMRC was not known. GOLD
suggested that mMRC score 2 and CAT score 10 were
sufficiently equivalent for the purpose of separating high
and low symptom patients, however a large recent study
shows that this is not the case and the mMRC equivalent to
CAT 10 is mMRC 1 [14]. Our data show a very similar
picture, with an mMRC score of 2 being approximately
equal to a CAT score of 22. The mMRC 2 cut-point (On
level ground, I walk slower than people of the same age
because of breathlessness, or have to stop for breath when
walking at my own pace) classified more patients as having
low symptoms than using a CAT score 10. With the latter,
only 10% of patients were placed in the low symptom groups
(GOLD groups A and C), compared to using the mMRC 2
which placed 51% of patients in these groups.
The distribution of patients across GOLD groups appears
to differ by sample population. In a report of two research
cohorts (ECLIPSE and COPDgene), using a SGRQ threshold of
25 (equivalent to CAT 10), 29% of COPD patients fell in57%
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important to recognise that COPDgene included partici-
pants who were recruited through various mechanisms
including general public and advertising and screening of
primary care and pulmonary clinics. In persons diagnosed
with COPD in the Copenhagen City Heart Study and the
Copenhagen General Population Study, 77% were in GOLD A,
when classified using mMRC 2. In a third retrospective
cohort study of patients identified from 11 study cohorts in
Spain, 34% of patients were graded GOLD Group A using
mMRC 2 [11]. It is clear that the proportion of patients in
the different GOLD groups will depend on the study popu-
lation. Ours is the first report in a routine care population.
The importance of this is reflected in the observation made
in a Spanish screening study, which showed that SGRQ
scores were much worse in patients with a prior diagnosis of
COPD compared to individuals identified as having COPD
through screening [16].
Preventing exacerbations has become a major objective
in the management of COPD patients [17]. For most clinical
studies, a history of 1 or more exacerbation has been used
to select subjects likely to exacerbate again [18e20]. The
ECLIPSE study observed that patients with 1 exacerbation in
the previous year had greater than 60% chance of21%
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Figure 2 Distribution of group C & D subtypes based on risk criteria (symptoms assessed using mMRC).
COPD population categorised using GOLD framework 133exacerbating in the following year [4]. Cote and colleagues
reported that a history of 1 exacerbation in the preceding
year had negative impacts on health status and outcomes
[17] and in the TORCH study, the rate of decline of FEV1 was
greater in patients with a low exacerbation rate compared
to those with none at all [21]. In our study population,
approximately one quarter of the patients in the low risk
groups had 1 exacerbation in the previous year, which
would fail to be included in GOLD high risk category. This
may have important clinical implications if one exacerba-
tion per year does produce adverse medium to long-term
outcomes. Half of our patients reported one or more ex-
acerbations in the preceding year, but it is noteworthy that
there were nearly twice as many patients who had two
or more compared to those who had only one. This may,
again, reflect the recruitment source. Patients with more
frequent exacerbations may be more likely to attend aTable 5 Patient allocation to groups A and C using CAT
and mMRC cut-points according to the GOLD 2013
recommendation.a
CAT mMRC
A B A B
Total, n 97 505 393 209
No exacerbations,
n (%)
83
(85.6)
368
(72.9)
311
(79.1)
140
(70.0)
1 Exacerbation,
n (%)
14
(14.4)
137
(27.1)
82
(20.9)
69
(33.0)
1 Exacerbation
that required
Emergency
department or
hospitalisation,
n (%)
1
(1.0)
24
(4.7)
9
(2.3)
16
(7.6)
a Highest risk is hospitalisation for COPD exacerbation.clinic than those who exacerbate less frequently. It is also
noteworthy that in GOLD D patients, nearly 80% were
identified as being at high risk of exacerbations based on
their history, whereas in ECLIPSE-COPDgene, the proportion
was much lower e only about one third [10]. That may not
be surprising since a proportion of those patients were
identified through screening. On the other hand, our find-
ings may only be generalisable to populations of patients
with already diagnosed COPD since many of them will have
been identified because of recurrent exacerbations. After
applying the GOLD 2013 recommendations, which recognise
that one severe exacerbation requiring hospital admission
is sufficient to indicate high risk of subsequent exacerba-
tions [22], we observed a 4.2% (25 out of 605) change of the
patient’s categorisation from low risk patients (groups
A þ B) to high risk patients (groups C þ D). This was inde-
pendent of the symptom scale used. The meaning of this
move is clinically uncertain but could have treatment
implications.
Treatment of chronic diseases such as COPD is compli-
cated by the presence of co-morbidities [23] which may
have a direct impact on survival in COPD [24]. In our cohort,
co-morbidities were highly prevalent in all GOLD groups
showing that these comorbidities are not only present in
the most severe disease category (group D) but also in the
less severe disease category (group B). With greater
severity, either because of worse symptoms or increased
risk of future exacerbations, metabolic and cardiovascular
co-morbidities were more prevalent. By contrast, using
GOLD spirometric grades in a primary care setting, the rate
of comorbidities (all and cardiovascular only) was found to
be essentially the same across GOLD grades [25]. In addi-
tion, findings from data pooled from two large general (not
specifically COPD) population studies showed that group B
had higher mortality from cardiovascular disease and can-
cer compared to group C [9]. Subgroup B, characterised by
more severe dyspnoea, had significantly poorer survival
than group C, in spite of a higher FEV1 level [9].
Table 6 Metabolic and cardiovascular co-morbidities by GOLD group (symptoms assessed by CAT and mMRC score).
GOLD group Diabetes % Hypertension % Hyperlipidaemia % Coronary artery
disease %
CAT mMRC CAT mMRC CAT mMRC CAT mMRC
A 4.1 13.0 38.1 49.9 13.4 24.9 3.1 4.8
B 15.8 15.8 55.4 57.9 29.5 30.6 5.5 5.7
C 0 18.7 14.3 59.7 14.3 38.8 0 6.5
D 28.5 32.3 65.3 66.7 37.3 36.0 9.0 10.0
Chi-squared 42.0 43.3 31.8 20.0 23.4 14.2 7.3 7.7
p-Value <0.001 <0.001 <0.001 <0.001 <0.001 0.003 0.062 0.053
134 P.W. Jones et al.Our data suggest that there is a link between COPD
severity and the prevalence of co-morbidity, but only when
COPD is assessed more broadly than just using spirometric
criteria. This warrants further investigation.
We recognise that there are limitations of using this
dataset, some of which have previously been published
[12]. In our study population, approximately 6 in 10 pa-
tients were recruited via pulmonary specialists so possibly
represent the more severe spectrum of patients Mild pa-
tients may have been less likely to have had a spirometry
assessment in the previous 12 months so would not have
been included, which again may bias the data toward a
more severe population. This is unlikely as 80% of patients
were classed as GOLD stage 1 or 2 by FEV1 predicted. We
identified few patients in group C suggesting that patients
with poor lung function and/or frequent exacerbations
generally do not report good health status. Approximately
80% of patients in our cohort were on maintenance therapy
and since treatment improves FEV1, symptoms and reduces
the rate of exacerbations, our analysis represents that of a
treated population. Recently published comparative anal-
ysis of four different cohorts pointed out that the preva-
lence of GOLD groups depends on the specific population
studied, with C being less prevalent [26]. This can partially
explain why we observed so little patients in C group in our
cohort.
In summary, the great majority of patients recruited from
routine practice in this analysis had a level of symptoms that
showed significantly impaired health status. A cut point
based on a CAT score of10 was not equivalent to one based
on an mMRC score 2. Of patients with high symptoms,
approximately one third were at high risk of exacerbations
based on a history of 2 exacerbations in the previous 12
months and an additional 20% reported one exacerbation in
the previous year. Comparison with other patient pop-
ulations shows adifferentdistributionof patients, depending
on setting. A high prevalence of cardiovascular and meta-
bolic co-morbidities was also observed in our cohort which
increased with both symptoms and risk of exacerbations,
although there were too few patients in category C to fully
assess this. These observations have important implications
for the assessment of COPD patients.Conflict of interest
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